ID   CBLC_HUMAN              Reviewed;         474 AA.
AC   Q9ULV8; Q8N1E5; Q9Y5Z2; Q9Y5Z3;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 3.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL-C;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173};
DE   AltName: Full=RING finger protein 57;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL-C {ECO:0000305};
DE   AltName: Full=SH3-binding protein CBL-3;
DE   AltName: Full=SH3-binding protein CBL-C;
DE   AltName: Full=Signal transduction protein CBL-C;
GN   Name=CBLC; Synonyms=CBL3, RNF57;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TYR-405.
RX   PubMed=10571044; DOI=10.1016/S0378-1119(99)00356-X;
RA   Kim M., Tezuka T., Suzuki Y., Sugano S., Hirai M., Yamamoto T.;
RT   "Molecular cloning and characterization of a novel cbl-family gene,
RT   cbl-c.";
RL   Gene 239:145-154(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), VARIANT TYR-405,
RP   FUNCTION AS EGF SIGNALING NEGATIVE REGULATOR, PHOSPHORYLATION BY EGFR
RP   (ISOFORM 1), TISSUE SPECIFICITY, AND INTERACTION WITH CRK AND LYN.
RC   TISSUE=Pancreatic adenocarcinoma;
RX   PubMed=10362357; DOI=10.1038/sj.onc.1202753;
RA   Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M.,
RA   Penninger J., Lipkowitz S.;
RT   "cbl-3: a new mammalian cbl family protein.";
RL   Oncogene 18:3365-3375(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION AS E3 UBIQUITIN-PROTEIN LIGASE, CATALYTIC ACTIVITY,
RP   INTERACTION WITH SRC, AUTOUBIQUITINATION, AND MUTAGENESIS OF GLY-276;
RP   TYR-341 AND CYS-351.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-
RT   dependent protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [5]
RP   FUNCTION IN RET STABILITY, INTERACTION WITH RET, AND MUTAGENESIS OF
RP   GLY-276 AND CYS-351.
RX   PubMed=18753381; DOI=10.1523/JNEUROSCI.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the
RT   regulation of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, DOMAIN, INTERACTION
RP   WITH UBE2D2 AND UBE2D3, PHOSPHORYLATION AT TYR-341, AND MUTAGENESIS OF
RP   TYR-341.
RX   PubMed=20525694; DOI=10.1074/jbc.M109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by
RT   modulating affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOUBIQUITINATION, PHOSPHORYLATION AT
RP   TYR-341, INTERACTION WITH TGFB1I1, AND MUTAGENESIS OF TYR-341; CYS-351
RP   AND CYS-366.
RX   PubMed=23145173; DOI=10.1371/journal.pone.0049428;
RA   Ryan P.E., Kales S.C., Yadavalli R., Nau M.M., Zhang H., Lipkowitz S.;
RT   "Cbl-c ubiquitin ligase activity is increased via the interaction of
RT   its RING finger domain with a LIM domain of the paxillin homolog, Hic
RT   5.";
RL   PLoS ONE 7:E49428-E49428(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 9-323 IN COMPLEX WITH EGFR
RP   PEPTIDE.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR
RT   py1069 peptide.";
RL   Submitted (OCT-2010) to the PDB data bank.
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) OF 1-323 IN COMPLEX WITH
RP   CALCIUM; SRC AND EGFR PEPTIDES, CALCIUM-BINDING, INTERACTION WITH EGFR
RP   AND SRC, AND MUTAGENESIS OF TYR-244; ARG-264; PRO-265; SER-266;
RP   THR-268 AND GLY-276.
RX   PubMed=22888118; DOI=10.1093/jb/mvs085;
RA   Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M.,
RA   Yamanashi Y., Yamamoto T., Nakagawa A.;
RT   "Structural flexibility regulates phosphopeptide-binding activity of
RT   the tyrosine kinase binding domain of Cbl-c.";
RL   J. Biochem. 152:487-495(2012).
CC   -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase, which accepts
CC       ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then
CC       transfers it to substrates promoting their degradation by the
CC       proteasome. Functionally coupled with the E2 ubiquitin-protein
CC       ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal
CC       transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1,
CC       but not isoform 2, inhibits EGF stimulated MAPK1 activation.
CC       Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In
CC       collaboration with CD2AP may act as regulatory checkpoint for Ret
CC       signaling by modulating the rate of RET degradation after ligand
CC       activation; CD2AP converts it from an inhibitor to a promoter of
CC       RET degradation; the function limits the potency of GDNF on
CC       neuronal survival. {ECO:0000269|PubMed:10362357,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:14661060,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:23145173}.
CC   -!- ENZYME REGULATION: Phosphorylation at Tyr-341 is necessary and
CC       sufficient for the activation of E3 activity.
CC       {ECO:0000269|PubMed:20525694}.
CC   -!- SUBUNIT: Interacts with ubiquitin-conjugating enzyme E2 UBE2D2 and
CC       UBE2D3. Isoform 1 interacts with EGFR (tyrosine phosphorylated).
CC       Interacts with the SH3 domain proteins LYN and CRK. Interacts (via
CC       RING-type zinc finger) with TGFB1I1 (via LIM zinc-binding domain
CC       2); the interaction is direct and enhances the E3 activity.
CC       Interacts directly with RET (inactive) and CD2AP; dissociates from
CC       RET upon RET activation by GDNF which also increases the
CC       interaction with CD2AP suggesting dissociation as CBLC:CD2AP
CC       complex. Interacts with SRC; the interaction is enhanced when SRC
CC       is phosphorylated at 'Tyr-419'. {ECO:0000269|PubMed:10362357,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:20525694, ECO:0000269|PubMed:22888118,
CC       ECO:0000269|PubMed:23145173, ECO:0000269|Ref.8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Long;
CC         IsoId=Q9ULV8-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=Q9ULV8-2; Sequence=VSP_005732;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:10362357}.
CC   -!- DOMAIN: EF-hand-like and Sh2-like domains are required for N-
CC       terminal inhibition of E3 activity. {ECO:0000269|PubMed:20525694}.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding
CC       (PTB) domain, a short linker region and the RING-type zinc finger.
CC       The PTB domain, which is also called TKB (tyrosine kinase binding)
CC       domain, is composed of three different subdomains: a four-helix
CC       bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00839,
CC       ECO:0000269|PubMed:20525694}.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on multiple tyrosine residues by SRC. Isoform
CC       1, but not isoform 2, is phosphorylated on tyrosines by EGFR.
CC   -!- PTM: Autoubiquitinated when phosphorylated at Tyr-341, enhanced by
CC       SRC; suggesting proteasomal degradation.
CC       {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694,
CC       ECO:0000269|PubMed:23145173}.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding
CC       site.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLcID194.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB028645; BAA86298.1; -; mRNA.
DR   EMBL; AF117646; AAD34341.1; -; mRNA.
DR   EMBL; AF117647; AAD34342.1; -; mRNA.
DR   EMBL; BC028915; AAH28915.1; -; mRNA.
DR   CCDS; CCDS12643.1; -. [Q9ULV8-1]
DR   CCDS; CCDS46109.1; -. [Q9ULV8-2]
DR   RefSeq; NP_001124324.1; NM_001130852.1. [Q9ULV8-2]
DR   RefSeq; NP_036248.3; NM_012116.3. [Q9ULV8-1]
DR   UniGene; Hs.466907; -.
DR   PDB; 3OP0; X-ray; 2.52 A; A/B=9-323.
DR   PDB; 3VRN; X-ray; 1.64 A; A=1-323.
DR   PDB; 3VRO; X-ray; 1.80 A; A=1-323.
DR   PDB; 3VRP; X-ray; 1.52 A; A=1-323.
DR   PDB; 3VRQ; X-ray; 2.39 A; A/B=1-323.
DR   PDB; 3VRR; X-ray; 2.00 A; A=1-323.
DR   PDBsum; 3OP0; -.
DR   PDBsum; 3VRN; -.
DR   PDBsum; 3VRO; -.
DR   PDBsum; 3VRP; -.
DR   PDBsum; 3VRQ; -.
DR   PDBsum; 3VRR; -.
DR   ProteinModelPortal; Q9ULV8; -.
DR   SMR; Q9ULV8; -.
DR   BioGrid; 117156; 46.
DR   IntAct; Q9ULV8; 20.
DR   MINT; MINT-247027; -.
DR   STRING; 9606.ENSP00000270279; -.
DR   iPTMnet; Q9ULV8; -.
DR   PhosphoSitePlus; Q9ULV8; -.
DR   BioMuta; CBLC; -.
DR   DMDM; 125987803; -.
DR   EPD; Q9ULV8; -.
DR   PaxDb; Q9ULV8; -.
DR   PeptideAtlas; Q9ULV8; -.
DR   PRIDE; Q9ULV8; -.
DR   DNASU; 23624; -.
DR   Ensembl; ENST00000270279; ENSP00000270279; ENSG00000142273. [Q9ULV8-1]
DR   Ensembl; ENST00000341505; ENSP00000340250; ENSG00000142273. [Q9ULV8-2]
DR   GeneID; 23624; -.
DR   KEGG; hsa:23624; -.
DR   UCSC; uc002ozs.4; human. [Q9ULV8-1]
DR   CTD; 23624; -.
DR   GeneCards; CBLC; -.
DR   H-InvDB; HIX0202847; -.
DR   HGNC; HGNC:15961; CBLC.
DR   HPA; CAB008087; -.
DR   HPA; HPA035266; -.
DR   MIM; 608453; gene.
DR   neXtProt; NX_Q9ULV8; -.
DR   OpenTargets; ENSG00000142273; -.
DR   PharmGKB; PA26117; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00390000011617; -.
DR   HOGENOM; HOG000294176; -.
DR   HOVERGEN; HBG005255; -.
DR   InParanoid; Q9ULV8; -.
DR   KO; K04707; -.
DR   OMA; WQHSDSQ; -.
DR   OrthoDB; EOG091G06R9; -.
DR   PhylomeDB; Q9ULV8; -.
DR   TreeFam; TF314210; -.
DR   SignaLink; Q9ULV8; -.
DR   SIGNOR; Q9ULV8; -.
DR   GeneWiki; CBLC; -.
DR   GenomeRNAi; 23624; -.
DR   PRO; PR:Q9ULV8; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000142273; -.
DR   CleanEx; HS_CBLC; -.
DR   Genevisible; Q9ULV8; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IDA:BHF-UCL.
DR   GO; GO:0001784; F:phosphotyrosine binding; IDA:BHF-UCL.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; IEA:InterPro.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   CDD; cd00162; RING; 1.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; SH3-binding; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    474       E3 ubiquitin-protein ligase CBL-C.
FT                                /FTId=PRO_0000055866.
FT   DOMAIN        7    321       Cbl-PTB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00839}.
FT   CA_BIND     199    210
FT   ZN_FING     351    390       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        7    145       4H.
FT   REGION      146    218       EF-hand-like.
FT   REGION      219    321       SH2-like.
FT   REGION      322    350       Linker.
FT   REGION      351    474       Interaction with RET.
FT                                {ECO:0000269|PubMed:18753381}.
FT   BINDING     264    264       Phosphotyrosine.
FT   MOD_RES     341    341       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   VAR_SEQ     261    306       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10362357}.
FT                                /FTId=VSP_005732.
FT   VARIANT     405    405       H -> Y (in dbSNP:rs3208856).
FT                                {ECO:0000269|PubMed:10362357,
FT                                ECO:0000269|PubMed:10571044}.
FT                                /FTId=VAR_018298.
FT   MUTAGEN     244    244       Y->A: Abolishes interaction with EGFR.
FT                                Decreases interaction with SRC and
FT                                abolishes SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     244    244       Y->F: No effect on interaction with EGFR
FT                                and SRC as well as on SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     264    264       R->A: Abolishes interaction with EGFR.
FT                                Decreases interaction with SRC and
FT                                abolishes SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     265    265       P->L: Enhances interaction with EGFR and
FT                                SRC as well as SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     266    266       S->A: Decreases interactions with EGFR
FT                                and SRC as well as SRC ubiquitination.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     268    268       T->A: Abolishes interaction with EGFR.
FT                                Decreases interaction with and
FT                                ubiquitination of SRC.
FT                                {ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     276    276       G->E: No effect on interaction with RET.
FT                                Binds slightly to SRC, this interaction
FT                                is independent of SRC phosphorylation.
FT                                Strongly decreases SRC ubiquitination.
FT                                Abolishes interaction with EGFR.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:18753381,
FT                                ECO:0000269|PubMed:22888118}.
FT   MUTAGEN     341    341       Y->E: Induces E3 activity and
FT                                autoubiquitination. Releases ubiquitin-
FT                                conjugating enzyme E2 UBE2D2 faster.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     341    341       Y->F: Abolishes activation by EGF
FT                                stimulation and enhancement by TGFB1I1 of
FT                                E3 activity.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     341    341       Missing: Abolishes E3 activity.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:20525694,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     351    351       C->A: No effect on TGFB1I1 and SRC
FT                                interactions. Abolishes SRC
FT                                ubiquitination. Abolishes interaction
FT                                with TGFB1I1; when associated with A-366.
FT                                Abolishes interaction with RET and
FT                                inhibition of RET degradation.
FT                                {ECO:0000269|PubMed:14661060,
FT                                ECO:0000269|PubMed:18753381,
FT                                ECO:0000269|PubMed:23145173}.
FT   MUTAGEN     366    366       C->A: Abolishes interaction with TGFB1I1.
FT                                Abolishes interaction with TGFB1I1; when
FT                                associated with A-351.
FT                                {ECO:0000269|PubMed:23145173}.
FT   CONFLICT    234    234       N -> T (in Ref. 1; BAA86298).
FT                                {ECO:0000305}.
FT   CONFLICT    413    413       S -> P (in Ref. 3; AAH28915).
FT                                {ECO:0000305}.
FT   HELIX        13     31       {ECO:0000244|PDB:3VRP}.
FT   STRAND       40     42       {ECO:0000244|PDB:3OP0}.
FT   HELIX        44     62       {ECO:0000244|PDB:3VRP}.
FT   STRAND       64     66       {ECO:0000244|PDB:3VRP}.
FT   HELIX        76     97       {ECO:0000244|PDB:3VRP}.
FT   STRAND      100    102       {ECO:0000244|PDB:3OP0}.
FT   HELIX       108    111       {ECO:0000244|PDB:3OP0}.
FT   HELIX       116    138       {ECO:0000244|PDB:3VRP}.
FT   HELIX       140    142       {ECO:0000244|PDB:3VRP}.
FT   TURN        146    148       {ECO:0000244|PDB:3VRP}.
FT   HELIX       154    164       {ECO:0000244|PDB:3VRP}.
FT   STRAND      168    171       {ECO:0000244|PDB:3VRP}.
FT   HELIX       172    179       {ECO:0000244|PDB:3VRP}.
FT   TURN        180    182       {ECO:0000244|PDB:3VRP}.
FT   HELIX       189    198       {ECO:0000244|PDB:3VRP}.
FT   STRAND      203    207       {ECO:0000244|PDB:3VRP}.
FT   HELIX       208    217       {ECO:0000244|PDB:3VRP}.
FT   HELIX       221    223       {ECO:0000244|PDB:3VRP}.
FT   HELIX       224    232       {ECO:0000244|PDB:3VRP}.
FT   STRAND      238    241       {ECO:0000244|PDB:3VRQ}.
FT   HELIX       244    251       {ECO:0000244|PDB:3VRP}.
FT   HELIX       252    254       {ECO:0000244|PDB:3VRP}.
FT   STRAND      260    265       {ECO:0000244|PDB:3VRP}.
FT   STRAND      267    269       {ECO:0000244|PDB:3VRP}.
FT   STRAND      273    278       {ECO:0000244|PDB:3VRP}.
FT   STRAND      284    287       {ECO:0000244|PDB:3VRP}.
FT   HELIX       294    303       {ECO:0000244|PDB:3VRP}.
FT   HELIX       320    323       {ECO:0000244|PDB:3OP0}.
SQ   SEQUENCE   474 AA;  52456 MW;  202634AEDE434544 CRC64;
     MALAVAPWGR QWEEARALGR AVRMLQRLEE QCVDPRLSVS PPSLRDLLPR TAQLLREVAH
     SRRAAGGGGP GGPGGSGDFL LIYLANLEAK SRQVAALLPP RGRRSANDEL FRAGSRLRRQ
     LAKLAIIFSH MHAELHALFP GGKYCGHMYQ LTKAPAHTFW RESCGARCVL PWAEFESLLG
     TCHPVEPGCT ALALRTTIDL TCSGHVSIFE FDVFTRLFQP WPTLLKNWQL LAVNHPGYMA
     FLTYDEVQER LQACRDKPGS YIFRPSCTRL GQWAIGYVSS DGSILQTIPA NKPLSQVLLE
     GQKDGFYLYP DGKTHNPDLT ELGQAEPQQR IHVSEEQLQL YWAMDSTFEL CKICAESNKD
     VKIEPCGHLL CSCCLAAWQH SDSQTCPFCR CEIKGWEAVS IYQFHGQATA EDSGNSSDQE
     GRELELGQVP LSAPPLPPRP DLPPRKPRNA QPKVRLLKGN SPPAALGPQD PAPA
//
